CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).
  
  OVERVIEW OF ACTIVITY
  The clinical course of CLL and outcomes for patients vary widely, largely based on individual predictive and other risk factors, and in recent years the identification of cytogenetic abnormalities and their subsequent incorporation into traditional clinical staging systems have refined clinicians’ ability to determine prognosis. On the basis of an improved understanding of the biology of CLL, a number of novel agents and strategies have been investigated. Some of these efforts have proven successful and have already resulted in the availability of new agents for use in the clinic. However, vexing questions and clinical challenges are emerging along with these many exciting advances.
  
  To bridge the gap between research and patient care, this program features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Individualize the selection of systemic therapy for newly diagnosed CLL, considering patient- and disease-specific factors, including age, clinical presentation, biomarker profile and coexisting medical conditions.
  • Recall emerging Phase III data evaluating Bruton tyrosine kinase inhibitors as first-line treatment for patients with CLL, and discern how these agents can be optimally integrated into clinical care algorithms.
  • Appreciate recent therapeutic advances and related FDA approvals for CLL and hairy cell leukemia, and use this information to counsel patients regarding protocol and nonresearch therapy.
  • Evaluate available and emerging data with novel agents and combination approaches, and consider their potential roles in the clinical management of CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies for patients with CLL.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  Video Program: Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 2.5 (audio) and 2.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better. The corresponding video program is available as an alternative at ResearchToPractice.com/CLLUpdate219/Video.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better. The corresponding audio program is available as an alternative at ResearchToPractice.com/CLLUpdate219.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Professor Dr Stephan Stilgenbauer
  Ulm University
  Ulm, Germany
  Saarland University
  Homburg, Germany
  
  Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, F Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Novartis.
  
  Jennifer Woyach, MD
  Associate Professor
  Division of Hematology
  Department of Internal Medicine
  The Ohio State University Comprehensive Cancer Center
  Columbus, Ohio
  
  Consulting Agreement: Janssen Biotech Inc; Contracted Research: AbbVie Inc, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys.
  
  RESEARCH TO PRACTICE MODERATOR, CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, moderator, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: September 2019
  Expiration date: September 2020